Add to ORKG(immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditi
Contains fulltext : 71337.pdf (publisher's version ) (Open Access
Bortezomib (a.k.a. as velcade or PS-341) is used in the clinic to treat multiple myeloma (MM) and ma...
The 26S proteasome is a ubiquitous enzyme complex which is responsible for degrading proteins that r...
Background and objectives (Immuno) proteasomes play a crucial role in processing of key proteins inv...
OBJECTIVE: To describe the pharmacodynamic monitoring of (immuno)proteasome inhibition following tre...
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations o...
Objectives To investigate whether bortezomib, a proteasome inhibitor approved for treatment of multi...
Inhibition of proteasome by bortezomib increase chemosensitivity of bcr/abl positive human k562 chro...
AbstractProteasome inhibition is a novel and promising strategy for the treatment of cancer. Bortezo...
As treatment options in advanced systematic lupus erythematosus (SLE) are limited, there is an urgen...
Bortezomib, an inhibitor of proteasomes, has been reported to reduce autoantibody titers and to impr...
We performed a phase I study of a day (D) 1 and D4 bortezomib administration once every 2 weeks to d...
Bortezomib is a potent inhibitor of proteasomes currently used to eliminate malignant plasma cells i...
Following its success in multiple myeloma (MM), proteasome inhibition has become a topic of interest...
© 2015.The proteasome inhibitor Bortezomib is used to treat multiple myeloma (MM). Bortezomib inhibi...
Contains fulltext : 71337.pdf (publisher's version ) (Open Access
Bortezomib (a.k.a. as velcade or PS-341) is used in the clinic to treat multiple myeloma (MM) and ma...
The 26S proteasome is a ubiquitous enzyme complex which is responsible for degrading proteins that r...
Background and objectives (Immuno) proteasomes play a crucial role in processing of key proteins inv...
OBJECTIVE: To describe the pharmacodynamic monitoring of (immuno)proteasome inhibition following tre...
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations o...
Objectives To investigate whether bortezomib, a proteasome inhibitor approved for treatment of multi...
Inhibition of proteasome by bortezomib increase chemosensitivity of bcr/abl positive human k562 chro...
AbstractProteasome inhibition is a novel and promising strategy for the treatment of cancer. Bortezo...
As treatment options in advanced systematic lupus erythematosus (SLE) are limited, there is an urgen...
Bortezomib, an inhibitor of proteasomes, has been reported to reduce autoantibody titers and to impr...
We performed a phase I study of a day (D) 1 and D4 bortezomib administration once every 2 weeks to d...
Bortezomib is a potent inhibitor of proteasomes currently used to eliminate malignant plasma cells i...
Following its success in multiple myeloma (MM), proteasome inhibition has become a topic of interest...
© 2015.The proteasome inhibitor Bortezomib is used to treat multiple myeloma (MM). Bortezomib inhibi...
Contains fulltext : 71337.pdf (publisher's version ) (Open Access
Bortezomib (a.k.a. as velcade or PS-341) is used in the clinic to treat multiple myeloma (MM) and ma...
The 26S proteasome is a ubiquitous enzyme complex which is responsible for degrading proteins that r...